BRAINSTORM CELL THERAPEUTICS INC. 8-K

What Happened

• On May 15, 2026, Brainstorm Cell Therapeutics, Inc. (BCLI) announced its earnings and financial results for the quarter ended March 31, 2026.
• The company issued a press release with the quarterly results; the full text of that press release is furnished as Exhibit 99.1 to the Form 8-K and is incorporated by reference.

Key Details

• Filing date: May 15, 2026 (Form 8-K, Item 2.02).
• Reporting period: quarter ended March 31, 2026 (Q1 2026).
• Exhibit: Press Release dated May 15, 2026 provided as Exhibit 99.1.
• The Form 8-K also includes the Inline XBRL cover page data (Exhibit 104).

Why It Matters

• Quarterly results and the accompanying press release give investors the latest information on Brainstorm’s revenue, earnings, cash position and operational performance—data that can affect the company’s stock price and investment decisions.
• Retail investors should read the furnished press release (Exhibit 99.1) for the specific financial figures, management commentary, and any updates on operations or outlook.